Novo Nordisk (NVO.US) third quarter sales increased by 11% year on year.

According to the Securities Times APP, on Wednesday, Danish pharmaceutical giant Novo Nordisk (NVO.US) announced its financial report for the third quarter of 2025. The third quarter sales (calculated at fixed exchange rates) increased by 11% year-on-year to 74.976 billion Danish kroner; operating profit (calculated at fixed exchange rates) decreased by 21% year-on-year to 23.682 billion Danish kroner; net profit was 20.006 billion Danish kroner, a decrease of 27% year-on-year.